This study examines people with no cognitive difficulties, mild cognitive impairment or Alzheimer’s disease who have genetics that causes Alzheimer’s disease. The goal is to test the safety and effectiveness of new study drugs, including antibodies targeting the protein amyloid-beta that builds up in the brains of people with Alzheimer’s disease. The study also aims to observe participants over time to monitor their daily function and to find ways to improve diagnosis.
Eligibility- Who can participate?
Participants must:
be between the ages of 18 and 80 years
know they have an Alzheimer’s disease-causing mutation or be unaware of their genetic status and have an autosomal dominant Alzheimer’s disease gene mutation in their family (genetic or autopsy report required)
have no cognitive issues, mild cognitive impairment or mild dementia
Time requirement
Maximum of 17 visits over 4 years or less. The visits will include brain imaging, cognitive testing, neurological and physical exams, and taking biosamples (i.e. blood, urine)
TDRA Study Investigator
Dr. Mario Masellis
Video
Advances in Dementia Research Webinar- Listen to Dr. Mario Masellis (Co-Principal Investigator) discuss the DIAN-TU study in further detail: https://www.youtube.com/watch?v=UuvjuVTcEU4
